Literature DB >> 18670745

Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients.

Luca Degrate1, Cinzia Nobili, Claudio Franciosi, Roberto Caprotti, Fernando Brivio, Fabrizio Romano, Biagio Eugenio Leone, Rosangela Trezzi, Franco Uggeri.   

Abstract

BACKGROUND AND AIMS: Innate immunity cells play a crucial role in host anticancer defense: cancer patients with high levels of natural killer (NK) cells and eosinophils have a better prognosis. Recombinant interleukin-2 (rIL-2) immunotherapy stimulates innate immunity cells. This study aims to evaluate the toxicity of pre- and postoperative rIL-2 treatment and the effects on innate immunity both in peripheral blood and in cancer tissue of patients with resectable pancreatic adenocarcinoma.
MATERIALS AND METHODS: Seventeen patients received high dose rIL-2 preoperative subcutaneous administration and two low dose postoperative cycles. We evaluated NK cell and eosinophil count in blood and in pancreatic surgical specimens.
RESULTS: Toxicity was moderate. In the early postoperative period, blood NK cells and eosinophils significantly increased compared to basal values (p < 0.02). Histopathological analysis did not find significant intratumoral infiltration of NK cells nor of eosinophils.
CONCLUSIONS: Preoperative high dose rIL-2 administration is able to counteract surgery-induced deficiency of NK cells and eosinophils in peripheral blood in the early postoperative period, although it cannot overcome local mechanisms of immune tumor escape in cancer tissue. The amplification of innate immunity, induced by immunotherapy, may improve the control of metastatic cells spreading in the perioperative period.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18670745     DOI: 10.1007/s00423-008-0393-4

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  51 in total

1.  Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.

Authors:  F Brivio; P Lissoni; G Alderi; S Barni; F Lavorato; L Fumagalli
Journal:  Oncology       Date:  1996 Jul-Aug       Impact factor: 2.935

2.  Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue.

Authors:  H J Nielsen; U Hansen; I J Christensen; C M Reimert; N Brünner; F Moesgaard
Journal:  J Pathol       Date:  1999-12       Impact factor: 7.996

3.  Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma.

Authors:  C Buzio; S Andrulli; R Santi; L Pavone; R Passalacqua; D Potenzoni; F Ferrozzi; R Giacosa; A Vaglio
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

Review 4.  The instructive role of innate immunity in the acquired immune response.

Authors:  D T Fearon; R M Locksley
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

Review 5.  Immune cell functions in pancreatic cancer.

Authors:  J M Plate; J E Harris
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

6.  Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.

Authors:  R T Davey; D G Chaitt; S C Piscitelli; M Wells; J A Kovacs; R E Walker; J Falloon; M A Polis; J A Metcalf; H Masur; G Fyfe; H C Lane
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

7.  Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer.

Authors:  K Iwasaki; M Torisu; T Fujimura
Journal:  Cancer       Date:  1986-09-15       Impact factor: 6.860

8.  Effect of antitumor surgery on soluble interleukin-2 receptor serum levels.

Authors:  F Brivio; P Lissoni; D Mancini; E Tisi; G Tancini; S Barni; V Nociti
Journal:  Am J Surg       Date:  1991-04       Impact factor: 2.565

9.  Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

Authors:  N J Meropol; G M Barresi; T A Fehniger; J Hitt; M Franklin; M A Caligiuri
Journal:  Cancer Immunol Immunother       Date:  1998-08       Impact factor: 6.968

10.  Serum levels of interleukin-2 in cancer patients: preliminary considerations.

Authors:  P Lissoni; S Viviani; A Santoro; S Barni; G Tancini
Journal:  Int J Biol Markers       Date:  1989 Oct-Dec       Impact factor: 3.248

View more
  10 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 2.  Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma.

Authors:  Lei Zheng; Jing Xue; Elizabeth M Jaffee; Aida Habtezion
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

Review 3.  Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Wanxing Duan; Jianjun Lei; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer.

Authors:  Cong-Jun Wang; Chao Wang; Jiang Han; Yong-Kun Wang; Lin Tang; Dong-Wei Shen; Yi Zhao; Rong-Hua Xu; Hui Zhang
Journal:  Mol Biol Rep       Date:  2013-10-18       Impact factor: 2.316

5.  Suppression of Gingival NK Cells in Precancerous and Cancerous Stages of Pancreatic Cancer in KC and BLT-Humanized Mice.

Authors:  Kawaljit Kaur; Hui-Hua Chang; Jessica Cook; Guido Eibl; Anahid Jewett
Journal:  Front Immunol       Date:  2017-12-04       Impact factor: 7.561

6.  Deficiencies in Natural Killer Cell Numbers, Expansion, and Function at the Pre-Neoplastic Stage of Pancreatic Cancer by KRAS Mutation in the Pancreas of Obese Mice.

Authors:  Kawaljit Kaur; Hui-Hua Chang; Paytsar Topchyan; Jessica Morgan Cook; Andre Barkhordarian; Guido Eibl; Anahid Jewett
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 7.561

7.  Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated Pancreatic Tumors in Hu-BLT Mice.

Authors:  Kawaljit Kaur; Anna Karolina Kozlowska; Paytsar Topchyan; Meng-Wei Ko; Nick Ohanian; Jessica Chiang; Jessica Cook; Phyu Ou Maung; So-Hyun Park; Nicholas Cacalano; Changge Fang; Anahid Jewett
Journal:  Cancers (Basel)       Date:  2019-12-24       Impact factor: 6.639

8.  The antitumor activity of hPRDX5 against pancreatic cancer and the possible mechanisms.

Authors:  Lihua Cui; Yuanyuan Jin; Sen Zou; Jing Xun; Xiangyang Yu; Qi Zhang; Zhaoyong Yang
Journal:  Braz J Med Biol Res       Date:  2022-09-12       Impact factor: 2.904

Review 9.  Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.

Authors:  Inga Hochnadel; Uta Kossatz-Boehlert; Nils Jedicke; Henrike Lenzen; Michael P Manns; Tetyana Yevsa
Journal:  Hum Vaccin Immunother       Date:  2017-11-07       Impact factor: 3.452

10.  DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma.

Authors:  Jianyu Yang; Yongsheng Jiang; Ruizhe He; Wei Liu; Minwei Yang; Lingye Tao; Xueliang Fu; Yang Shen; Jiao Li; Dejun Liu; Yanmiao Huo; Junfeng Zhang; Rong Hua; Zhigang Zhang; Yongwei Sun
Journal:  J Immunol Res       Date:  2019-09-08       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.